CÁNCER DE MAMA
Institute Catalá Oncología
Barcelona, EspañaPublications en collaboration avec des chercheurs de Institute Catalá Oncología (33)
2024
-
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer
JAMA network open, Vol. 7, Núm. 4, pp. e247811
-
Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
eClinicalMedicine, Vol. 71
2023
2022
2021
2019
-
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients
Aging, Vol. 11, Núm. 9, pp. 2874-2888
-
Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer
Journal of Clinical Medicine, Vol. 8, Núm. 12
-
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125
-
The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin
Frontiers in Oncology, Vol. 9, Núm. MAR
2018
-
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study
Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704
-
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
Breast Cancer Research and Treatment, Vol. 168, Núm. 2, pp. 357-364
2017
-
A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study
Oncotarget, Vol. 8, Núm. 42, pp. 73144-73153
-
Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy
Journal of Clinical Oncology
2015
-
Population-based multicase-control study in common tumors in Spain (MCC-Spain): Rationale and study design
Gaceta Sanitaria, Vol. 29, Núm. 4, pp. 308-315
2014
-
Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors
Medical Oncology, Vol. 31, Núm. 1
-
Phase lb study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy
Clinical Cancer Research, Vol. 20, Núm. 7, pp. 1935-1945
2013
-
Basal/HER2 breast carcinomas Integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin)
Cell Cycle, Vol. 12, Núm. 2, pp. 225-245
-
Eribulin mesylate in breast cancer
Women's Health, Vol. 9, Núm. 6, pp. 517-526
-
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study
Journal of Clinical Oncology
2012
-
Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice
Breast Cancer Research and Treatment, Vol. 134, Núm. 3, pp. 1161-1168